UCSF UC San Francisco Previously Published Works

Title

MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide

Permalink

https://escholarship.org/uc/item/1967v4xc

Journal

BMC Pharmacology and Toxicology, 14(Suppl 1)

ISSN 2050-6511

Authors

Arora, Pankaj Wu, Connie Bloch, Donald B <u>et al.</u>

Publication Date 2013-08-01

DOI

10.1186/2050-6511-14-s1-o10

Peer reviewed

ORAL PRESENTATION



MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide

Pankaj Arora^{1,2,3,4}, Connie Wu⁵, Donald B Bloch^{6,7}, Brandi N Davis-Dusenbury⁸, Ester Spagnolli⁵, Akiko Hata⁹, Sara Vandenwijngaert¹⁰, Melissa Swinnen¹⁰, Stefan Janssens¹⁰, Emmanuel S Buys⁵, Kenneth D Bloch^{1,2,5*†}, Christopher Newton-Cheh^{1,2,3,4†}, Thomas J Wang^{1,2†}

From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Erfurt, Germany. 28-30 June 2013

Background

Numerous common genetic variants have been linked to blood pressure, but no underlying mechanism has been elucidated. Population studies have revealed that a genetic variant, rs5068 (A/G), is associated with blood pressure and the risk of hypertension. rs5068 lies in the 3' untranslated region (3'UTR) of *NPPA*, the gene encoding atrial natriuretic peptide (ANP), and presence of the minor G allele is associated with increased circulating ANP levels and reduced blood pressure.

Results

We hypothesized the existence of a microRNA (miR) that targets the NPPA 3'UTR and that the binding of the miR to the NPPA 3'UTR would be disrupted in transcripts from the rs5068 minor allele. We identified a microRNA, miR-425, that is predicted to bind the sequence spanning rs5068 for the A, but not the G, allele. miR-425 is expressed in human atria and ventricles. Using luciferase-3'UTR reporter constructs, we observed that miR-425 could silence reporter mRNAs carrying the NPPA major allele 3'UTR, but not those carrying the minor allele 3'UTR. Similarly, an anti-miR directed against miR-425 augmented expression of the luciferase-NPPA 3'UTR construct containing the major allele but not the minor allele. miR-425 reduced NPPA mRNA levels and ANP synthesis in human cardiomyocytes derived from induced pluripotent stem cells.

Conclusion

Our studies provide mechanistic insights into how a common genetic variant identified in population genetic studies can regulate ANP levels and blood pressure. miR-425 is a novel regulator of ANP production, raising the possibility that miR-425 antagonists could be used to treat disorders of salt overload, including hypertension and heart failure.

Authors' details

¹Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA. ²Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA. ³Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA. ⁵Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁶Division of Rheumatology, Allergy, and Clinical Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁶Division of Rheumatory Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁸Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁹Cardiovascular Research Institute, University, Gambridge, Massachusetts, USA. ¹⁰Department of Cardiovascular Sciences, Gasthuisberg University Hospital, University of Leuven, Belgium.

Published: 29 August 2013

doi:10.1186/2050-6511-14-S1-O10 Cite this article as: Arora *et al.*: MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide. *BMC Pharmacology and Toxicology* 2013 14(Suppl 1):O10.

Full list of author information is available at the end of the article



© 2013 Arora et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

^{*} Correspondence: kdbloch@partners.org

[†] Contributed equally

¹Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA